ArriVent BioPharma Inc. (AVBP)
ArriVent BioPharma Inc. (AVBP) Stock Price, Analysis & Data
| Bid | 22.54 |
| Market Cap | 1.47B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -145.24M |
| Beta | 1.37 |
| EPS (ttm) | -3.38 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.04 |
| P/B (ttm) | 4.40 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2026 |
| Ask | 38.95 |
| Volume | 289,229 |
| Avg. Volume (20D) | 562,527 |
| Open | 31.18 |
| Previous Close | 31.39 |
| Day's Range | 30.86 - 31.60 |
| 52-Week Range | 16.64 - 35.83 |
| Analyst | Strong Buy |
| Price Target | 45 (43.04%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), ...
Financial Performance
In 2025, ArriVent BioPharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -166.31M, an increase of 106.62%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for AVBP stock is "Strong Buy". The 12-month stock price forecast is 45, which is upside of 43.04% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
